Josh advises entrepreneurs to help them build their businesses and complete successful fundraising transactions and exit events.

Josh’s practice focuses on representing founders and start-ups. He serves as outside corporate counsel to his clients, functioning as their general counsel throughout the lifecycle of their businesses to help them develop effective legal and business strategies, solve problems, and complete deals that advance their business goals. He regularly advises clients regarding company formation and early-stage legal issues, financings (including angel, venture capital. and strategic investments) and mergers and acquisitions.

Josh typically works with companies in the life sciences industry — drug development, devices, diagnostics and tools — and in the technology sector, including digital health, software, and technology-enabled services. He has helped numerous clients, including the following, to grow and thrive:  

• Aquinnah Pharmaceuticals
• Asimov
• Axoft
• Bilayer Therapeutics
• Droplette
• Hopewell Therapeutics
• InGel Therapeutics
• MediSix Therapeutics
• NanoView Biosciences
• NextGen Jane
• New Equilibrium Biosciences
• PanTher Therapeutics
• Quaise Energy
• Stemloop
• Suono Bio
• Syntis Bio
• Teal Bio
• Verseau Therapeutics

In addition to counseling entrepreneurs and emerging companies, Josh represents investors, including venture capital firms and foundations, in the investments that they make. Notable investor-side clients include Lightstone Ventures and The Mark Foundation for Cancer Research.

He frequently speaks on topics related to entrepreneurship, financing, exit strategies, and best practices for businesses.

Josh also maintains an active pro bono practice, is involved in the firm’s hiring activities and is a lecturer at the Boston University School of Law, where he teaches a class on venture capital financings that he created.